2.72Open2.72Pre Close0 Volume2 Open Interest1.50Strike Price0.00Turnover376.03%IV2.43%PremiumDec 20, 2024Expiry Date2.62Intrinsic Value100Multiplier20DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.9443Delta0.0310Gamma1.50Leverage Ratio-0.0103Theta0.0006Rho1.41Eff Leverage0.0011Vega
Geron Stock Discussion
Almost low enough
Geron Corp - Receives $250 Million at Closing, $125 Million in Debt Available
Royalty Pharma to Acquire Royalty Interest in Geron’s Rytelo for $125 Million
Achieved $28.2 million in RYTELO(TM) (imetelstat) net product revenue in first full quarter of sales
Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt
No comment yet